{"title":"Nitric oxide-releasing NSAIDs: a novel class of GI-sparing anti-inflammatory drugs.","authors":"J L Wallace, Q J Pittman, G Cirino","doi":"10.1007/978-3-0348-7276-8_12","DOIUrl":null,"url":null,"abstract":"<p><p>The addition of a nitric oxide-releasing moiety to a number of common nonsteroidal anti-inflammatory drugs markedly reduces their toxicity in the gastrointestinal tract without interfering with their ability to inhibit prostaglandin synthesis. Moreover, the anti-inflammatory and anti-pyretic activities of the nitric-oxide releasing NSAID were comparable to the parent compound, while the anti-thrombotic activity in vivo was significantly enhanced. Nitric oxide-releasing NSAIDs may represent an alternative to existing anti-inflammatory, anti-pyretic and anti-thrombotic agents with greatly reduced toxicity in the gastrointestinal tract.</p>","PeriodicalId":7491,"journal":{"name":"Agents and actions. Supplements","volume":"46 ","pages":"121-9"},"PeriodicalIF":0.0000,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"28","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Agents and actions. Supplements","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/978-3-0348-7276-8_12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 28
Abstract
The addition of a nitric oxide-releasing moiety to a number of common nonsteroidal anti-inflammatory drugs markedly reduces their toxicity in the gastrointestinal tract without interfering with their ability to inhibit prostaglandin synthesis. Moreover, the anti-inflammatory and anti-pyretic activities of the nitric-oxide releasing NSAID were comparable to the parent compound, while the anti-thrombotic activity in vivo was significantly enhanced. Nitric oxide-releasing NSAIDs may represent an alternative to existing anti-inflammatory, anti-pyretic and anti-thrombotic agents with greatly reduced toxicity in the gastrointestinal tract.